Galera Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017
Net Income	-59.08	-62.22	-80.53	-74.22	-59.11	-29.59	-28.13
Depreciation & Amortization	0.26	0.11	0.78	0.37	0.27	0.13	0.08
Share-Based Compensation	5.56	7.16	7.23	5.54	2.39	0.87	0.73
Other Operating Activities	8.42	11.52	4.57	8.78	2.61	0.52	-0.67
Operating Cash Flow	-44.85	-43.43	-67.96	-59.54	-46.66	-22.17	-23.41
Capital Expenditures	-0.06	-0.03	-0.28	-0.46	-0.63	-0.35	-0.32
Change in Investments	27.35	24.02	5.52	37	-27.19	-58.69	23.83
Investing Cash Flow	27.29	23.99	5.24	36.55	-27.83	-59.04	23.51
Share Issuance / Repurchase	31.5	3.89	9.21	0.51	58.03	0	0
Other Financing Activities	-	-	57.5	20	20	89.84	-
Financing Cash Flow	31.5	3.89	66.71	20.51	78.03	89.84	0
Net Cash Flow	13.94	-15.54	3.99	-2.48	3.55	8.64	0.11
Free Cash Flow	-44.91	-43.45	-68.24	-59.99	-47.29	-22.51	-23.73
Free Cash Flow Per Share	-1.01	-1.60	-2.65	-2.41	-13.05	-74.89	-78.93

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).